These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 37033971

  • 1. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.
    Tischer-Zimmermann S, Bonifacius A, Santamorena MM, Mausberg P, Stoll S, Döring M, Kalinke U, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B.
    Front Immunol; 2023; 14():878953. PubMed ID: 37033971
    [Abstract] [Full Text] [Related]

  • 2. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
    Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C.
    J Exp Med; 2001 Feb 05; 193(3):405-11. PubMed ID: 11157061
    [Abstract] [Full Text] [Related]

  • 4. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.
    Cytotherapy; 2014 Jan 05; 16(1):122-34. PubMed ID: 24094498
    [Abstract] [Full Text] [Related]

  • 5. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.
    J Exp Med; 2000 May 15; 191(10):1649-60. PubMed ID: 10811859
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S, Dieks D, Sukdolak C, Bunse C, Figueiredo C, Immenschuh S, Borchers S, Stripecke R, Maecker-Kolhoff B, Blasczyk R, Eiz-Vesper B.
    J Immunol Methods; 2014 Jun 15; 408():101-13. PubMed ID: 24877879
    [Abstract] [Full Text] [Related]

  • 7. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.
    Hum Immunol; 2005 Sep 15; 66(9):938-49. PubMed ID: 16360833
    [Abstract] [Full Text] [Related]

  • 8. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
    Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D.
    Am J Transplant; 2003 Nov 15; 3(11):1369-77. PubMed ID: 14525597
    [Abstract] [Full Text] [Related]

  • 9. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
    Messinger JE, Dai J, Stanland LJ, Price AM, Luftig MA.
    mBio; 2019 Jul 02; 10(4):. PubMed ID: 31266868
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cells for the induction of EBV immunity.
    Subklewe M.
    Recent Results Cancer Res; 2002 Jul 02; 159():38-43. PubMed ID: 11785842
    [Abstract] [Full Text] [Related]

  • 11. Induction of minor histocompatibility antigen-specific T-helper but not T-cytotoxic response is dependent on the source of antigen-presenting cell.
    van Els CA, Bakker A, van Rood JJ, Goulmy E.
    Hum Immunol; 1990 May 02; 28(1):39-50. PubMed ID: 2160446
    [Abstract] [Full Text] [Related]

  • 12. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
    Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ.
    Blood; 2000 Sep 01; 96(5):1857-64. PubMed ID: 10961887
    [Abstract] [Full Text] [Related]

  • 13. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
    Landais E, Saulquin X, Scotet E, Trautmann L, Peyrat MA, Yates JL, Kwok WW, Bonneville M, Houssaint E.
    Blood; 2004 Feb 15; 103(4):1408-16. PubMed ID: 14563644
    [Abstract] [Full Text] [Related]

  • 14. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells.
    Chen M, Shirai M, Liu Z, Arichi T, Takahashi H, Nishioka M.
    J Virol; 1998 Oct 15; 72(10):8301-8. PubMed ID: 9733874
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct 15; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.